Table 3. Association between IgM anti-PC and CLL in the nested case–control study.
| n | Raw value (U/ml) | Normalized value | |
|---|---|---|---|
| All | 120 | 40.72 (25.33−83.45) | 0.00 ± 0.99 |
| t-test | |||
| CLL cases | 30 | 29.35 (18.68−69.73) | -0.38 ± 1.11 |
| Matched controls | 90 | 42.30 (30.32−87.06) | 0.13 ± 0.92 |
| P | 0.015 | ||
| CLL prevalent cases | 7 | 22.29 (9.29−29.53) | -1.12 ± 1.10 |
| Matched controls | 21 | 46.20 (38.04−74.36) | 0.12 ± 0.90 |
| P | 0.006 | ||
| CLL incident cases | 23 | 31.73 (18.86−88.51) | -0.15 ± 1.04 |
| Matched controls | 69 | 41.74 (27.67−91.26) | 0.13 ± 0.93 |
| P | 0.227 | ||
| CLL incident cases (>5 years)a | 11 | 29.77 (18.86−144.23) | -0.18 ± 1.09 |
| Matched controls | 33 | 38.72 (27.67−69.25) | 0.05 ± 0.84 |
| P | 0.471 | ||
| Stratified Cox proportional hazards model (CLL incident cases and matched controls) | |||
| Hazard ratio (95% CI) | 92 | 1.00 (0.99−1.01) | 0.75 (0.40-1.39) |
| P | 0.421 | 0.354 | |
Nested case–control study includes three age- and sex-matched controls for each CLL case. The distribution of raw IgM anti-PC value is skewed, so median (interquartile range, the 25th percentile–75th percentile) is used to describe the distribution. Mean6SD is used to describe the distribution of rank order normalized values of IgM anti-PC. Follow-up time is the years between dates of blood sampling and first CLL diagnosis.
a
Only cases with more than 5 years between sampling and diagnosis are included.